Immunoregulation of Inflammation in Chronic Kidney Disease
1Department of Advanced Nephrology and Regenerative Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
2Division of Nephrology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA
3Department of Immunology, Kitasato University School of Medicine Sagamihara, Japan
Immunoregulation of Inflammation in Chronic Kidney Disease
Description
Chronic kidney disease (CKD) is one of the most commonly encountered diseases in clinical practice. It is estimated that one out of every ten adults in the world, that is, about 600 million people, suffer from CKD. There has been a marked increase in the number of patients showing progression to end-stage renal disease and requiring hemodialysis or other renal replacement therapy. There was a rapid, approximately 5-fold increase, in the number of persons requiring hemodialysis from 1990 until 2010. Also, CKD patients with or without diabetes are at a high risk of developing hypertension and other cardiovascular diseases, which can influence the life prognosis. CKDs are frequently treated with steroids and/or immunosuppressive agents. However, there are no established treatment regimens for CKDs induced by various underlying causes. Therefore, investigation of “immunoregulation of inflammation” is very important to develop novel treatment strategies for CKD. As one of the factors of the immune system, nuclear factor-kappa B (NF-kB) plays a central role in inflammation and regulates various key factors such as cytokine, chemokine, and cellular apoptosis. A thorough knowledge and understanding of immunoregulation of inflammation in CKD may lead to resolution of the mechanism of occurrence of CKD and provision of better care to patients.
We invite investigators to contribute original research articles as well as review articles that may serve as valuable resources to understand the development of treatment strategies for CKD. We are interested in articles exploring all aspects of the immune system related to the development of CKD in both humans and animal models. Potential topics include, but are not limited to:
- Role of inflammation in CKDs derived from various causes, including diabetic nephropathy
- Immunopathogenesis of CKD such as Lupus nephritis, anti-GBM glomerulonephritis, and ANCA-associated pauci-immune glomerulonephritis
- Role of the immune system in local cell such as tubular, mesangial, or podocyte cell injury induced by various stimulations
- Study of the mechanisms and pathways of transcriptional regulation of NF-kB in CKD
- Role of apoptosis in inflammation associated with the development of CKD
- Immune biomarkers for diagnosis, prediction of prognosis, and prediction of response to therapies in patients with CKD
- Development of immunotherapeutic strategies for CKDs
- Regenerative therapy based on immune responses in CKDs
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/author/submit/journals/cdi/ckd/ according to the following timetable: